R&D channel feed

What PDU­FA date? Clo­vis shares surge as PARPs get trendy on Wall Street

9 years ago

Neoanti­gens beck­on Mer­ck in­to a $200M can­cer col­lab­o­ra­tion with Mod­er­na

9 years ago

Gale­na im­plodes as tri­al mon­i­tors call a halt to a failed PhI­II can­cer study

9 years ago

Tesaro rock­ets up af­ter PARP in­hibitor aces PhI­II study and R&D ri­val­ry in­ten­si­fies

9 years ago

Es­pe­ri­on tanks on warn­ing that the road to an FDA de­ci­sion could be much, much longer than they thought

9 years ago

Two flops in two weeks for Mar­i­nus Phar­ma­ceu­ti­cal­s' ganax­olone 

9 years ago

In lat­est set­back for stem cell sec­tor, Celyad fails PhI­II— and the biotech claims a vic­to­ry

9 years ago

No­var­tis inks a $2.5B bis­pe­cif­ic can­cer drug de­vel­op­ment al­liance with Xen­cor

9 years ago

Third time the charm? An­a­lyst says a mar­ket­ing de­ci­sion is “im­mi­nent” for Sarep­ta’s Duchenne drug eteplirsen

9 years ago
Pharma

GW Phar­ma’s ral­ly rolls on as cannabi­noid drug scores again in PhI­II Epid­i­olex an­ti-con­vul­sive study

9 years ago

Scor­ing the 5 top phase III drugs in the glob­al pipeline

9 years ago
Pharma

Gary Glick gets $27M to leap back in­to im­muno-on­col­o­gy R&D with No­var­tis, At­las and Abing­worth in his cor­ner

9 years ago
People

An­ti­fun­gal play­er F2G banks $60M, eyes IPO in lead­up to a PhI­II tri­al

9 years ago
Financing

Sean Park­er finds a big role to play in can­cer R&D: The dis­rup­tive bil­lion­aire

9 years ago
People

Cir­cas­sia shares crum­ble as PhI­II flop blights the sec­tor once again

9 years ago

Epizyme says it’s ex­cit­ed by PhII da­ta, but there’s plen­ty to fret about

9 years ago
First page Previous page 328329330331
A service from the Financial Times